About this trial
Patients in the study receive the usual AML treatment of azacitidine and venetoclax, together with either revumenib or a placebo. Researchers want to find out whether the addition of revumenib improves outcomes for people with AML that carries NPM1 or KMT2A genetic abnormalities and who cannot receive intensive chemotherapy.
Patient Profile
Adults aged 18 years or older who have newly diagnosed AML and has not yet received treatment for it. Their leukemia contains a particular genetic abnormality (NPM1 or KMT2A), and because of their age, overall health, or other medical conditions, standard intensive chemotherapy is not considered the best option for them.
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Galway, University Hospital Waterford, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | HOVON 177 (EVOLVE-2) |
|---|---|
| Number: | 24-92 |
| Full Title: | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
| Principal Investigator: | Dr. Janusz Krawczyk |
|---|---|
| Type: | Collaborative |
| Sponsor: | HOVON |
| Recruitment Started: |
Global: July 2026 Ireland: June 2026 |
| Global Recruitment Target: | 415 |
|---|---|
| Ireland Recruitment Target: | 12 |